The U.S. Food and Drug Administration approved Veppanu (vepdegestrant), a Pfizer‑Arvinas combination therapy, for adults with estrogen‑receptor‑positive, HER2‑negative, ESR1‑mutated advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy. The approval also includes the Guardant360 CDx companion diagnostic, which identifies ESR1 mutations required for patient selection.
Veppanu represents Arvinas’s first FDA‑approved drug and the first PROTAC (proteolysis‑targeting chimera) therapy to reach the market, validating the company’s protein‑degradation platform. For Pfizer, the approval expands its oncology portfolio into a niche yet high‑growth segment, creating a new revenue stream and reinforcing its strategy to deepen its breast‑cancer offerings.
The approval was based on the Phase 3 VERITAC‑2 trial, in which Veppanu produced a median progression‑free survival of 5.0 months versus 2.1 months for fulvestrant, translating into a 43 % reduction in the risk of disease progression or death. The data demonstrate a clinically meaningful benefit for a population with limited second‑line options.
Arvinas received a $50 million milestone payment from Pfizer and is pursuing a third‑party partner to commercialize Veppanu, positioning the drug for broad market access. The early approval, ahead of the June 5 PDUFA date, underscores the strength of the clinical evidence and the companies’ confidence in the product’s commercial potential.
The competitive landscape for ESR1‑mutated breast cancer remains sparse; few therapies address this specific mutation after endocrine resistance. Veppanu’s PROTAC mechanism offers a distinct therapeutic approach, potentially capturing a sizable share of the unmet‑need market and providing a differentiated option for patients and clinicians.
"Together with Pfizer, we are on track to announce selection of a third party to bring this new treatment option to patients as soon as possible," said Randy Teel, CEO of Arvinas. "This milestone demonstrates that targeted protein degradation can translate into meaningful clinical impact and strengthens our confidence in the breadth of our oncology pipeline."
Erika Hamilton, M.D., Chief Development Officer at Sarah Cannon Research Institute, noted the scarcity of second‑line options for patients with ESR1‑mutated disease, highlighting the significance of Veppanu’s approval for this patient group.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.